LFG
LXEO icon

Larson Financial Group’s Lexeo Therapeutics LXEO Stock Holding History

Larson Financial Group’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.36K Buy
1,456
+1,216
+507% +$8.62K ﹤0.01% 2348
2025
Q4 		$2.38K Buy
240
+235
+4,700% +$2.14K ﹤0.01% 2726
2025
Q3 		$33 Buy
+5
New +$24 ﹤0.01% 3373

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Larson Financial Group's LXEO Position: Q1 2026 in Review

Larson Financial Group increased its Lexeo Therapeutics (LXEO) stake by 507% in Q1 2026, buying an estimated $8.62K and bringing the position to 1,456 shares worth $8.36K. The position accounts for ﹤0.01% of the portfolio, ranked #2348.

Larson Financial Group first reported a position in LXEO in Q3 2025 and has held it in 3 quarters since. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Larson Financial Group held 1,456 shares of Lexeo Therapeutics worth $8.36K as of Q1 2026.
  • Larson Financial Group bought 1,216 Lexeo Therapeutics shares in Q1 2026, an estimated $8.62K.
  • Lexeo Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #2348 holding.
  • Larson Financial Group first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.